Product Description
Mechanisms of Action: HCV-NS5B Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hepatitis A|Hepatitis C, Chronic|Liver Cirrhosis|Hepatitis C
Phase 2: Hepatitis C, Chronic|Hepatitis A
Phase 1: Hepatitis C, Chronic|Healthy Volunteers|Kidney Diseases|Hepatitis A
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT01858961 | P3 |
Withdrawn |
Hepatitis C, Chronic |
2016-07-01 |
|
2012-003534-17 | P2 |
Completed |
Hepatitis C, Chronic |
2016-06-08 |
|
2012-003533-41 | P3 |
Completed |
Liver Cirrhosis |
2015-01-22 |
|
HCVerso1 | P3 |
Completed |
Hepatitis C, Chronic |
2015-01-01 |